PacificHealth Laboratories, Inc. company was founded in 1995 and is based in Matawan, New Jersey. PacificHealth Laboratories, Inc. engages in the development, marketing, and sale of protein-based nutritional products for appetite regulation. It principally focuses on sports performance, weight loss, and management of Type II diabetes. The company offers ENDUROX R4, a recovery drink; ACCELERADE, a sports drink; ACCEL GEL, an energy gel; and ENDUROX EXCEL, a dietary supplement. PacificHealth Laboratories sells its products through retail outlets, including GNC, sports specialty stores, independent health food retailers, independent bike retailers, health clubs, catalogs, and Internet sites, as well as through independent distributors.

Phase 2 Discovery partners with pharmaceutical companies to develop early-stage drug candidates that could treat various central nervous system diseases and conditions. The company also acquires drug candidates, takes them through Phase I and II clinical studies, and then offers the company the option of re-acquiring them Phase 2's goal is to speed up the discovery process for multiple compounds that could aid patients with psychiatric and neurological disorders.

GlaxoSmithKline Pharmaceuticals (GSK India) is the top of the pill heap. India's leading pharmaceutical manufacturer, the company makes pharmaceuticals and consumer health care products through its two manufacturing facilities in Nashik and Thane; it also has a clinical development center in Bangalore. Its products include those targeting problems with infections, gynecology, dermatology, diabetes, and the cardiovascular system. Top sellers are Augmentin, Zinetac, Calpol, Phexin, and Betnesol. GSK India also makes vaccines to treat or prevent hepatitis A and B, the flu, chickenpox, and tetanus. Its distribution network stretches throughout the country. UK-based drugmaker GlaxoSmithKline owns GSK India.

MediGene develops drugs that save lives or just make life easier. Spun off from the Munich Gene Center in 1994, MediGene focuses its R&D efforts on therapies that battle various forms of cancer and autoimmune conditions. It also has several drugs on the market, many of them sold through partnerships with other drug firms. The company's Eligard treatment for prostate cancer is sold in Europe by Astellas Pharma, and its Veregen ointment for genital warts is on the US market (Bradley Pharmaceuticals (now part of Nycomed US) sells the drug). In 2008 MediGene won approval from European regulatory authorities for Oracea, a treatment for rosacea; it sold European marketing rights for the drug to Galderma Laboratories.

InterMune, Inc. company was founded in 1998 and is headquartered in Brisbane, California. InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The company has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes CAPACITY, a Phase III program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF; and a research program focusing on pirfenidone analog ITMN-520. The hepatology portfolio comprises the HCV protease inhibitor compound ITMN-191, which is in Phase Ib, a second-generation HCV protease inhibitor research program; and a research program evaluating a new target in hepatology. It has license and collaboration agreements with Maxygen Holdings Ltd.; Array BioPharma, Inc.; Boehringer Ingelheim International GmbH; Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Novartis Corporation; Connetics Corporation; Eli Lilly & Company; Genentech, Inc.; ALZA Corporation; Amgen Inc; and Marnac, Inc. and its co-licensor, /KDL GmbH.

Tongjitang Chinese Medicines Company was founded in 1995 and is headquartered in Shenzhen, the People's Republic of China. Tongjitang Chinese Medicines Company, through its subsidiaries, engages in the development, manufacture, marketing, and sale of Chinese medicines, nutritional products, and Tibetan recipe-originated plant-based medicines in the People’s Republic of China. The company also involves in the wholesale and retail of medicines. It offers Xianling Gubao for the treatment of osteoporosis, osteoarthritis, ischemic bone necrosis, and bone fractures; Zaoren Anshen Capsules for the treatment of insomnia; and moisturizing and anti-itching Capsules for the treatment of inflammatory skin conditions. The company also produces and sells Dianbaizhu Syrup for the treatment of vertigo; Compound Glycyrrhiza oral solution for the treatment of upper respiratory infections; Jiao Ti Guo Jiao Bi Capsules that prevent gastritis and ulcers; Bu Shen Yi Lao capsules, which improve memory, breathing, hearing, and general malaise; Xin Nao Kang capsules for the treatment of stroke and coronary artery disease; Jincishen Mixture used as an ancillary to treatment of cancer; Heiguteng capsules for the treatment of rheumatoid arthritis; Chongcao Qingfei capsules for the treatment of Chronic Obstructive Pulmonary Disease; Fengshi Gutong capsules for the treatment of rheumatoid arthritis; and Jingshu Granules for treatment of degenerative osteoarthritis. In addition, its product pipeline candidates comprise Jing Tong Ting, a phase III clinical trial product for menstrual pain; Da An Granules, a phase III ongoing product for anxiety; Yushuda Tablets, a phase III ongoing product for depression; and Dan Xian Kang Gu Capsules, a phase III design ongoing product for ischemic necrosis.

CEO Marc Coucke co-founded Omega Pharma NV company in 1987. Omega Pharma's first product was generic shampoo, which it sold to pharmacies. Omega Pharma NV is a Belgium-based provider of healthcare products and services for the pharmacies and other medical sectors. The Company specializes in the development, marketing and sales of health and personal care products, which can be obtained by the end-consumer without medical prescription (over the counter or OTC products). Omega Pharma NV consists of five business units, and is engaged in the provision of consumer-oriented medicines and healthcare products. It is composed of Omega Pharma Belgium, Omega Pharma France, Omega Pharma Northern Europe, Omega Pharma Southern Europe and Omega Pharma Rest of the World. As of December 31, 2008, the Company operated in over 30 countries, including most of the European countries, as well as Australia, New Zealand and Argentina.

Blansett Pharmacal Co., Inc. company's products include respiratory drugs Prolex and Nalex, tension headache remedy Anolor, and swimmer's ear treatment Cortane. Blansett also makes medications for women's health and hemorrhoids. On top of developing its own products, the company markets under-promoted products developed by other pharmaceutical companies. Blansett Pharmacal was founded in 1982 in North Little Rock, Arkansas; its products are distributed throughout the US.

Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.